Clinical trials: Triple Negative Breast Cancer, open to volunteers
TNBC, Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined…
- Trial name
- NCT06682195
- Testing
- Neoadjuvant chemotherapy combined with Toripalimab
- Where
- 13 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
This is a prospective, open-label, single-center, phase II, randomized controlled clinical trial involving patients with triple-negative breast cancer who meet the criteria for neoadjuvant chemotherapy (T > 2 cm, N+).
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy
- Trial name
- NCT07884201
- Testing
- Thymalfasin
- Volunteers
- 572 people
- Sponsor
- Fudan University
HER2-negative Breast Cancer, Metastatic Breast Cancer
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced…
- Conditions
- HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05660083
- Testing
- L-NMMA
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- The Methodist Hospital Research Institute
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer…
- Trial name
- NCT06492759
- Testing
- Radiation Therapy, Pembrolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Triple Negative Breast Cancer
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast…
- Trial name
- DIAMOND (NCT06954480)
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Durvalumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Queen Mary University of London
Adenocarcinoma of the Breast, Breast Cancer
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
- Conditions
- Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07768436
- Testing
- CMF Regimen, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumors
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with…
- Trial name
- NCT06840821
- Testing
- MB0151 for injection
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Mainline Biosciences (Shanghai) Co., Ltd
Triple Negative Breast Cancer
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin.
- Trial name
- TARMAC (NCT06291064)
- Testing
- Cyclophosphamide, Epirubicin, Docetaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Breast Cancer Invasive
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
The primary aim is to evaluate the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy in patients with triple-negative breast cancer, with the endpoint being the pCR rate-defined as the…
- Trial name
- NCT06691594
- Testing
- neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC)…
- Trial name
- NCT05633654
- Testing
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Where
- 376 sites in United States, Australia and 10 more
- Volunteers
- 1,514 people
- Sponsor
- Gilead Sciences
Triple Negative Breast Neoplasms
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease…
- Trial name
- CAPPA (NCT05973864)
- Testing
- Pembrolizumab injection, Capecitabine tablets, Local radiotherapy
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- UNICANCER
Breast Cancer Triple Negative
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
This is a randomized phase II study to evaluate the disease control rate (DCR) of patients with metastatic or locally advanced METHYLATED 06-methylguanine-DNA methyltransferase (MGMT) with triple-negative breast cancer (TNBC)…
- Trial name
- NCT05128734
- Testing
- Temozolomide, Olaparib
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- AHS Cancer Control Alberta
TNBC - Triple-Negative Breast Cancer
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC…
- Trial name
- NCT06627712
- Testing
- SBRT+PD-1 Inhibitor + Chemotherapy, PD-1 Inhibitor + Chemotherapy
- Where
- China
- Volunteers
- 318 people
- Sponsor
- West China Hospital
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT03606967
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Triple-Negative Breast Neoplasm
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs.
- Trial name
- KEY-MELT (NCT07011823)
- Testing
- Partial breast-irradiation
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD204 in participants with selected solid tumours, to…
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 5 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
TNBC - Triple-Negative Breast Cancer
Trop-2 Targeted PET Probes in Advanced TNBC
According to inclusion and exclusion criteria, 20 eligible subjects with triple-negative breast cancer (TNBC) scheduled to receive sacituzumab govitecan were screened.
- Trial name
- NCT07046455
- Testing
- Sacituzumab Govitecan (SG)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Triple Negative Breast Cancer
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer…
- Trial name
- NCT05909332
- Testing
- Antivascular therapy, Chemotherapy
- Where
- 15 sites in China
- Volunteers
- 764 people
- Sponsor
- Fudan University